TURGUT OZAL MEDICAL CENTER PEDIATRIC BONE MARROW TRANSPLANTATION UNIT
Pediatric Bone Marrow Transplantation
Bone marrow transplantation is a vital treatment method for children who are struggling with bone marrow function, including leukemia, certain solid tumors, immune system disorders, certain metabolic diseases, and other blood disorders.
PEDIATRIC BONE MARROW TRANSPLANTATION CENTER
Bone marrow transplants are needed for the precise treatment of leukemia, lymphoma, MDS, aplastic anemia, thalassemia, hemophagous lymphocystic stenosis and a significant portion of congenital immunodeficiencies. Inonu University Medical Faculty Turgut Ozal Medical Center Children's Bone Marrow Transplantation Center, patients are evaluated in the bone marrow transplantation council and autologous, allogenic and non-relative bone marrow transplants are successfully carried out. In our center , Professor Dr. Arzu Akyay (head of the center), Dr. There are 6 nurses, including two faculty members, including Yurday Durma Pioneer (central responsible assistant), a bone marrow transplant coordinator and a therapeutic apheresis technician. Our center currently has nine hepatofiltrated patient rooms.
Types of Bone Marrow Transplantation:
1. Otolog (Kendinden Kendine) Nakil:
It's a transplant from a child's own healthy bone marrow or stem cells. Especially in lymphomas, neuroblastomas and similar high-risk tumors, the patient's bone marrow is first collected and frozen. Then high-dose chemotherapy is given, which cannot be given under normal conditions, the tumor is removed, and then the patient's pre-frozen stem cells are transplanted.
2. Allojenik (Bağışçıdan) Nakil:
Transplantation is the transfer of bone marrow or stem cells from another person (usually a sibling, close family member, or a genetically compatible donor).
Children who need bone marrow transplants:
• Cancers such as high-risk leukemia, lymphoma, neuroblastoma, brain tumors, Ewing's sarcoma, and Wilms' tumor
• Hemophagous lymphocytes (HLH)
• Myelodysplastic syndrome (MDS)
• Divorce
• Uterine anemia
• Aplastic anemia (deficiency of the kidneys)
• Immunodeficiency disorders (dysfunction of the immune system)
• Metabolic diseases (some rare genetic diseases)
• Congenital neutropenia
Nakil Süreci:
Preparation phase 1 (preparation mode):
It can be chemotherapy or radiotherapy depending on the disease of the child, which is done to destroy the diseased bone marrow and suppress the immune system.
Bone marrow or stem cell transplantation:
It's the stage where healthy stem cells are transplanted. The stem cells are collected from the peripheral veins of the arm by apheresis or transplanted to the recipient after the use of the spinal cord or stem cell enhancers in an operating environment. Within two to three weeks, the given stem cells adhere to their nests in the bone marrow to start the production of healthy blood cells.
3. İyileşme Süreci:
This process usually takes three to four weeks. Since the immune system is weak after a bone marrow transplant, the risk of infection is closely monitored. Blood transfusions are performed until new donor cells are produced. In addition, drug therapy (immunosuppressive therapy) is administered to adapt transplanted cells to the recipient.
Success Levels and Risks:
• Success rates vary depending on factors such as bone marrow transplantation, the child's age, general health status, type of disease, and genetic compatibility with the donor.
• There may be serious post-transplant complications, such as graft-versus-host disease (GVHD) and infections.
Bone marrow transplantation is a vital treatment method for survival of children, however, there may not always be a family-appropriate donor for this treatment, in which case voluntary donors are used as stem cell donors.
Kemik İliği Bağışı Nasıl Yapılır?
1. Bağışçı Kriterleri:
That's healthy individuals between the ages of 18 and 35,
It's people with all the medical conditions.
2. Bağış Süreci:
To be a donor, you are first tested to determine your tissue type (genetic compatibility).
If you ever get along with a patient after that test, you're invited to donate bone marrow.
Nerelerde Bağış Yapabilirim?
• If you apply to the Turkish Red Cross, your blood samples will be taken and you will be registered as a donor at TÜRKÖK (Turkish Root Cell Coordination Centre).
• Conclusion: Bone marrow transplantation in children is an important option in treating many diseases. Since each child's situation is different, the decision and process of the transplant must be considered by an expert team. The recovery process of the child after a bone marrow transplant should be closely monitored, taking into account the recovery of the immune system and the general state of health.
Hayata Dokunun!
• Donating bone marrow can help a child develop a healthy future!
• You too can be a hope as a stem cell donor!
________________________________________
The communication:
Elif Mengiler, Coordinator of the Children's Bone Transplant Center at the Turgut Ozal Medical Center
Tel: 0 422 3410660-5370-5385
________________________________________
Inönü university type faculty turgut special type center adult bone marrow transplant unit
Turgut Ozal Medical Center of Inonu University Medical Faculty completed the construction of the Bone Marrow Transplantation Center in itself and received a license from the Ministry of Health in 2010 and started the bone marrow transplantation. In our bone marrow transplant center, autologous, allogeneic, haploid and unrelated bone marrow transplants are successfully performed. In 2014, a total of 67 bone marrow transplants were performed, including 2 haploid, 27 allogeneic, and 38 autologous. In 2015, bone marrow transplants were started in our center. As of June 2015, there have been two unrelated transplants. One of these patients had a bone marrow transplant from Germany to the other from the United States. In 2015, a total of 67 patients received stem cell transplants. In 2016, a total of 74 patients received stem cell transplants. Of these, 25 are allogenic, 45 are autologous, 5 are unrelated, and one is haploid. A total of 301 bone marrow transplants have been performed so far since our facility was authorized. Our death rates from bone marrow transplants are American and European. In our center , Professor Dr. Mehmet Ali ERKURT, Prof.Dr. I'm not going to tell you. Emin KAYA and 3 faculty members, including 1 specialist doctor, therapeutic affairs technician, bone marrow transplant coordinator, 9 nurses and 2 service personnel are on duty. There are currently 12 patient beds in our facility. The number of beds for bone marrow transplants at the Oncology Hospital, which will be completed within a year, will increase to 26. Our hospital is equipped and staffed to perform all kinds of bone marrow transplants. Health tourism in our center will begin this year to serve patients with bone marrow transplants coming from neighboring countries. Inonu University Turgut Ozal Medical Center, Erishkin bone marrow transplantation center, is one of the leading centers in Turkey in the field of bone marrow transplantation and will continue to be ambitious in the field of health tourism.
Treatment and follow-up times by disease
Multiple Myeloma
Patients are treated with 4 cycles of Bortezomib, cyclophosphamide and dexamethasone, followed by an autologous stem cell transplant (OCIT). Each sphere lasts 21 days, and the patient is discharged, rested for a week, and then transferred to the other sphere. Each round takes a total of one month. 1 in the appropriate patients. Fourth. Eight. And the 11th. Treatments of the day can be given standing up. Inappropriate patients have to take all the treatments in bed. After four months of treatment, autologous stem cell transplants are performed in remission. It takes an average of 15 days to mobilize stem cells. Melphalan is used as a preparation mode for OCT. On average, patients are discharged 15 to 21 days after the procedure. A Multiple Myeloma patient completes treatment on average five to six months after being diagnosed.
Akut Myeloblastik Lösemi (AML)
Patients are receiving a round of remission-induction treatment (3+7). The average hospital stay is one month. Then a co-worker receives a high-dose treatment of sitarabine as a consolidation treatment. The average rest period is one month. Patients are discharged one week after each shift. If the patient is in remission, a complete bone marrow transplant is performed from the donor. In the absence of a fully compatible donor from the sibling, bone marrow is transplanted from a non-relative or haploid (partially compatible) donor. This treatment takes an average of a month. On average, an AML patient completes treatment three to four months after diagnosis. Patients are followed for a total of 6 months, especially the first 100 days after transplantation, one day a week.
Akut Lenfoblatik Lösemi (ALL)
Patients receive a two-course CALGB or Hyper CVAD regimen according to performance status. These treatments take an average of two months. Patients are discharged one week after each shift. If the patient is in remission, a complete bone marrow transplant is performed from the donor. In the absence of a fully compatible donor from the sibling, bone marrow is transplanted from a non-relative or haploid (partially compatible) donor. This treatment takes an average of a month. On average, an AML patient completes treatment three to four months after diagnosis. Patients are followed for a total of 6 months, especially the first 100 days after transplantation, one day a week.
Burkit Lenfoma
Patients in four circles CODOX- He's going to get M/IVAC chemotherapy. Each round lasts 21 days. After each round, patients are discharged and given a week's rest. This treatment takes an average of four months. It takes an average of 15 days to mobilize stem cells. The preparation mode is OKIT using the Bu-CY-Eto mode. On average, patients are discharged 15 to 21 days after the procedure. On average, a Burkitt lymphoma patient completes treatment five to six months after being diagnosed.
Noxious Non Hodgkin and Hodgkin lymphoma
Patients are given two courses of DHAP. After each round, patients are discharged and given a week's rest. This treatment takes an average of two months. Our patients are mobilized at the end of DHAP, so no additional mobilization regimen is needed. The preparation mode is OKIT using the Bu-CY-Eto mode. On average, patients are discharged 15 to 21 days after the procedure. On average, a patient with a pulmonary lymphoma completes treatment three months after diagnosis.
Our center also performs bone marrow transplants for patients with chronic myeloid leukemia, aplastic anemia, myelodisplastic syndrome, thalassemia, solid tumors and myelofibrosis who do not respond to medication.
مركز زراعة ونقل نقي العظام في جامعة اينونو مركز تورغوت اوزال للبحوث الطبية